Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Biogen’s patent claims is directed toward a drug treatment for multiple sclerosis. It is a forest-tree situation.

Patent Law 125

Patent Law Law Patent Invention 125

IPilogue

AUGUST 5, 2021

Psilocybin, an active compound in what is commonly known as “magic mushrooms”, is currently listed under Schedule III of Canada’s Controlled Drugs and Substances Act. Under this Act , it is illegal to possess, obtain, or produce psilocybin without a prescription or licence. In 2020, the sales of cannabis products hit $2.6

Patent 59

Patent Invention Journalism Ownership 59

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 21, 2020

For example, experts in the medical field believe that blockchain could facilitate drug development by making the results of clinical trials more widely accessible. [5] We may dive into this topic in a future blog post. [2] 101 before a wide range of examiners at the USPTO.

Technology 76

Technology Copying Invention Patent Prosecution 76

SpicyIP

JANUARY 2, 2022

This year, we have divided these developments into three categories: a) Top 10 IP Judgments/Orders (Topicality/Impact). Top 10 Judgments/Orders [Topicality/Impact]. Hetero Drugs Ltd [Delhi High Court]. Hetero Drugs claimed that the drug was not being used in India and the export was only for research and development purposes.

IP 143

IP Intellectual Property Copyright Trademark 143

SpicyIP

JULY 19, 2021

Topical Highlight. Nishtha emphasises that in determining whether the deceased possessed personality rights enforceable by his heirs, the Court based its reasoning on the intertwining between privacy and publicity rights. The Cinematograph (Amendment) Bill 2021: Overbroad, Disproportionate and Unnecessary. News from India.

Advertising 105

Advertising Advertising Non-Fungible Tokens Intellectual Property 105

Patently-O

NOVEMBER 11, 2022

The scope afforded to chemical genus claims under 35 USC § 112(a)’s enablement and written description requirements has been hot topic recently (at least in certain quarters). Again, the gist of this example comes from an actual Federal Circuit decision, Noelle v.

Inventor 48

Inventor Invention Patent Reporting 48

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Biosimilar Drug. In 2021, regulatory agencies focused on three interrelated issues: (1) decreasing anti-competitive behavior in the biosimilars space, (2) lowering biologic drug prices, and (3) providing further guidance to clarify the regulatory pathway for biosimilars. Tackling Biologic Drug Pricing. Reference Product.

Litigation 52

Litigation Settlement Patent Marketing 52